Fabry disease: Enzyme replacement therapy

Journal of the European Academy of Dermatology and Venereology

Volumn 17, Issue 6, 2003, Pages 676-679

  Bongiorno, M R ^a   Pistone, G ^a   Arico M ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Deficiency of galactosidase A; Enzyme replacement therapy; Fabry disease; Lysosomal storage disorder

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE; ANTIHISTAMINIC AGENT; CERAMIDE DERIVATIVE; CORTICOSTEROID; GALABIOSYLCERAMIDE; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; UNCLASSIFIED DRUG;

ADULT; ANHIDROSIS; ARTICLE; CASE REPORT; CORNEA DYSTROPHY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REPLACEMENT; EPIDEMIOLOGY; FABRY DISEASE; FAMILY HISTORY; FEMALE; FIBROBLAST; FOLLOW UP; HEART DISEASE; HEMANGIOKERATOMA; HEMIZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LYSOSOME STORAGE DISEASE; MALE; NEEDLE BIOPSY; NEUROLOGIC DISEASE; PARESTHESIA; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RIGOR; RISK ASSESSMENT; TREATMENT OUTCOME; VASOMOTOR DISORDER; X CHROMOSOME LINKED DISORDER;

ALPHA-GALACTOSIDASE; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FABRY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; MALE; RISK ASSESSMENT; SAMPLING STUDIES; TREATMENT OUTCOME;

EID: 0242456107     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.2003.00831.x     Document Type: Article

References (20)

1. Brady RO, Gal AE, Bradley RM et al. Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency. N Engl J Med 1967;276: 1163-1167.
2. Kint JA. Fabry's disease: alpha-galactosidase deficiency. Science 1970;167:1268-1269.
3. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, editors. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. McGraw-Hill, New York, 2001:3733-3774.
4. Wherrett JR, Hakomori SI. Characterization of a blood group B glycolipid accumulating in the pancreas of a patient with Fabry's disease. J Biol Chem 1973;248:3046-3051.
5. Ashton-Prolla P, Ashley GA, Giuliani R et al. Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG). Am J Med Genet 1999;84:420-424.
6. Macdermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-807.
7. Desnick RJ, Eng CM. Fabry disease: α-galactosidase A deficiency (Angiokeratoma corporis diffusum universale). In: Fitzpatrick's Dermatology in General Medicine, 5th ed., 1999;153: 1812-1825.
8. Fabry J. Ein Beitrag zur kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagichebrae). Arch Dermatol Syphilis 1898;43:187-200.
9. Anderson WA. A case of angiokeratoma. Br J Dermat 1898;18: 113-117.
10. Meroni M, Sessa A, Battini G et al. Kidney involvement in Anderson-Fabry disease. Contrib Nephrol 1997;122:178-184.
11. Nissenson AR, Port FK. Outcome of end stage renal disease in patients with rare causes of renal failure. Inherited and metabolic disorders. Q J Med 1989;73:1055-1062.
12. Sessa A, Meroni M, Battini G et al. Renal pathological changes in Fabry disease. J Inherit Dis 2001; 24 (Suppl. 2):66-70.
13. Chimenti C, Ricci R, Pieroni M et al. Cardiac variant of Fabry's disease mimicking hypertrophic cardiomyopathy. Cardiologia 1999;44:469-473.
14. Crutchfield KE, Patronas NJ, Dambrosia JM et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998;50:1746-1749.
15. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996;40:8-17.
16. Brown LK, Miller A, Bhuptani A et al. Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med 1977;155:1004-1007.
17. Brady RO, Tallman JF, Johnson WG et al. Replacement therapy for inherited enzyme deficiency: use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med 1973;289:9-14.
18. Desnick RJ, Dean KJ, Grabowski G et al. Enzyme therapy. XII. Enzyme therapy in Fabry's disease: differential enzyme and substrate clearance kinetics of plasma and splenic α-galactosidase isozymes. Proc Natl Acad Sci USA 1979;76:5326-5330.
19. Schiffmann R, Murray GJ, Treco D et al. Infusion of a galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000;97:365-370.
20. Schiffmann R, Kopp JB, Austin HA III et al. Enzyme replacement therapy in Fabry disease. A randomised controlled trial. J Am Med Assoc 2001;285:2743-2749.